Hohl Benjamin's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jul 1, 2024
- Accession no.
- 0001415889-24-018694
- Filed
- Jul 1, 2024
- Trade date
- Jun 27, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $95.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hohl BenjaminCIK 0001882764 | Officer (CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 27, 2024 | Common Stock | MOption exerciseAcquired | +4,250 | $2.48 | +$10,540 | 4,250 | Direct | |
| Jun 27, 2024 | Common Stock | SSaleDisposed | −1,280 | $21.79F2 | −$27,891.2 | 2,970 | Direct | |
| Jun 27, 2024 | Common Stock | SSaleDisposed | −1,830 | $22.58F3 | −$41,321.4 | 1,140 | Direct | |
| Jun 27, 2024 | Common Stock | SSaleDisposed | −1,140 | $23.43F4 | −$26,710.2 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 27, 2024 | Common Stock | MOption exerciseDisposed | −4,250 | $0.00 | $0 | 212,620 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $21.145 to $22.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $22.2058 to $23.1325. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $23.37 to $23.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.